treating fatigue in patients with malignant gliomas undergoing treatment with radiotherapy
plus temodar. Armodafinil is a wakefulness-promoting agent that has been FDA approved for
the treatment of excessive daytime sleepiness for a variety of disorders. Armodafinil may
also help to reduce radiation-induced fatigue in brain tumor patients.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.